New Chemical Entities (NCEs) &

Synthetic Methods

The discovery of a brand new compound (or class of compounds) with useful biological properties opens up the possibility of obtaining what is arguably the most robust form of pharmaceutical patent protection – a patent for the drug product per se. Such a patent provides a monopoly over manufacture, sale and use of the drug for any medical use, including potential future uses which might be identified during the lifetime of the patent.

Our team of pharmaceutical chemistry specialists have extensive experience in the drafting, filing and prosecution of patents for NCEs. We can advise on strategic aspects such as when to file and issues relating to the provision of supporting data, as well as on substantive issues of patentability.

Within our chemistry team there is also a wealth of experience in synthetic organic chemistry, with many of our team having backgrounds in natural product synthesis or synthetic methodology.

A further aspect of pharmaceutical innovation is the development of synthetic routes to the drug compounds. The discovery of a new synthetic pathway may provide access to further new compounds, or it may be a step towards an optimised manufacturing route to an already-discovered drug. Patent protection for a validated (GMP) manufacturing process can be a further useful tool for innovators seeking to safeguard their investment.

For a number of on-market pharma products we have handled all aspects of worldwide patent prosecution on behalf of large multi-national pharma clients. We also have substantial expertise in freedom-to-operate searching and due diligence in this area.

Validation_Strategies_for_Pharmaceutical_Patents_in_Europe-Compressed (1) copy

Special Report

Validation Strategies for Pharmaceutical Patents in Europe

The decision on where to validate a pharmaceutical European patent is a big one. With costs often precluding an “everywhere” approach for small- to medium-sized companies, research institutions and universities, it is necessary to choose from the long list of available countries. The choice typically factors in costs, business interests, likely markets and market size, possible manufacturing and import locations and the regulatory framework in Europe.

This report explores these choices and factors using publicly available data, seeking to answer questions such as:

  • Which countries are most commonly picked by patent holders at the EPO?
  • Is the distribution the same for pharmaceutical patents?
  • Where does “big pharma” choose to validate?
  • What factors might affect the choice of countries?
DOWNLOAD THE REPORT

Read our Blogs

The brilliant dawn of AI drug discovery

The brilliant dawn of AI drug discovery

Computer simulations are solving challenges previously thought uncrackable.

Updates to the Guidelines for Examination at the EPO

Updates to the Guidelines for Examination at the EPO

The Guidelines for Examination at the EPO (which will be referred to as “the Guidelines” in this article) elaborate on the various articles/rules of the European Patent Convention and provide ...

Most opposed patents of 2023

Most opposed patents of 2023

Multiple sclerosis therapies are the subject of two of the most opposed patents of 2023. Novartis’ EP2959894 is notable from a patent attorney perspective not only because it’s the subject of 23 ...

Pharma trade marks: 2023 EU case law round up

Pharma trade marks: 2023 EU case law round up

As we enter 2024, we reflect on the lessons we have learned in 2023. The trade mark landscape has continued to evolve, and pharmaceutical trade marks are no exception. In this article, we take a ...

Antibiotic with novel mechanism offers new hope for treating resistant infections

Antibiotic with novel mechanism offers new hope for treating resistant infections

This week saw the publication of a potential new class of antibiotics and their mechanism (Zampaloni et al., 2024, Pahil et al., 2024).

New highs for psychedelics in the clinic

New highs for psychedelics in the clinic

Psychedelic compounds have long been experimented with for their mind-altering properties, but in recent years, this theme of research has taken on a much more serious demeanour. It may be that ...

Learn More
Forward Magazines Overlapping 8

Mewburn Ellis

FORWARD MAGAZINE

Mewburn Ellis Forward is a biannual publication that celebrates the best of innovation and exploration. Through its pages we hope to inform and entertain, but also to encourage discussion about the most compelling developments taking place in the scientific and entrepreneurial world. Along the way, we’ll engage with the IP challenges that international organisations face every day.